MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Entry into a Material Definitive Agreement

On July 6, 2018, MabVax Therapeutics Holdings, Inc. (the “Company”) entered into and closed an Asset Purchase and License Agreement (the “Agreement”) with Boehringer Ingelheim International GmbH (“Boehringer Ingelheim”).

to the terms of the Agreement, Boehringer Ingelheim acquired all rights to the Company’s program targeting a glycan commonly overexpressed on multiple solid tumor cancers. Subject to the terms of the Agreement, the Company will receive an upfront payment of $4,000,000 plus near-term milestones, downstream regulatory milestones and further earn-out payments for a total of $11,000,000. The Agreement also contains provisions regarding payment terms, confidentiality and indemnification, as well as other customary provisions.

On July 9, 2018, the Company issued a press release announcing the signing of the Agreement with Boehringer Ingelheim.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

(d)Exhibits.

The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.

MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99 2 ex99-07092018_080703.htm Ex 99.1     Exhibit 99.1 MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers     SAN DIEGO,…To view the full exhibit click here